| Purpose | Board Meetings Date | Announcement Date |
|---|---|---|
| Board Meeting | 19 May 2025 | 13 May 2025 |
| Astal Laboratories Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 19/05/2025 inter alia to consider and approve the audited standalone financial results for the quarter and year ended March 31 2025 along with limited review report of the auditors and other businesses. Submission of intimation of appointment of Secretarial Auditor. Submission of outcome of the meeting of the board of directors held on Monday 19th May, 2025. Submission of audited financial results for the quarter and year ended 31 March, 2025. (As Per BSE Announcement Dated on: 19/05/2025) | ||
| Board Meeting | 27 Jan 2025 | 21 Jan 2025 |
| Quarterly Results Astal Laboratories Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 27/01/2025 ,inter alia, to consider and approve Submission of prior intimation of Board meeting to be held on 27th January 2025 to approve unaudited financial results for the quarter ended 31st December 2024. Submission of intimation of Board meeting outcome. Submission of unaudited financial results for the quarter ended 31st December 2024. (As per BSE Announcement Dated on 27/01/2025) | ||
| Board Meeting | 27 Nov 2024 | 22 Nov 2024 |
| Astal Laboratories Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 27/11/2024 inter alia to consider and approve Allotment of 4079930 Convertible Warrants convertible into equity shares of face value of Rs. 10/- each at premium of Rs. 30/- each to Strategic Investors (Non-Promoters) on Preferential basis. To discuss any other matter with the permission of the chairperson. Intimation of the Outcome of the Meeting of the Board held on 27th November, 2024 pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) (LODR) Regulations, 2015. (As Per BSE Announcement dated on 27.11.2024) | ||
| Board Meeting | 12 Nov 2024 | 6 Nov 2024 |
| Quarterly Results Submission of unaudited financial results for the quarter ended 30th September 2024. Intimation of outcome of Board Meeting held on 12th November 2024. (As Per BSE Announcement Dated on: 12/11/2024) | ||
| Board Meeting | 27 Jul 2024 | 20 Jul 2024 |
| Astal Laboratories Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 27/07/2024 inter alia to consider and approve the unaudited standalone financial results for the quarter ended 30th June 2024 along with Limited Review Report of the Auditors thereon. This is to inform that Board of Directors of the Company in its meeting held on 27th July, 2024 at the corporate office of the company i.e., 8-2-351/w/3/4, Road Number 3, Banjara Hills, Hyderabad, Telangana, 500034, which commenced at 5:00 P.M. has taken the Decisions mentioned in the outcome. (As Per BSE Announcement Dated on: 27/07/2024) | ||
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2025, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248, DP SEBI Reg. No. IN-DP-185-2016
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.